Emerging in the landscape of weight management therapy, retatrutide represents a distinct method. Different from many current medications, retatrutide functions as a double agonist, at once engaging both glucagon-like peptide-1 (GLP-1) and glucose-sensitive insulinotropic substance (GIP) binding sites. The concurrent engagement encourages various a